ImmunoGen has shaken off a previous phase 3 flop for its ovarian cancer antibody-drug conjugate Elahere with what its CEO is calling a “home run” trial success. ...

The battle between the makers of face-filling beauty products is getting ugly. Now, AbbVie is throwing a new wrinkle into the mix. The pharma giant is accusing Re...

The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2023) gathers top-level management from pharmaceutical companies of manufacturing, primary and secon...

In a surprise announcement Wednesday, Bristol Myers Squibb said its CEO Giovanni Caforio, M.D., will end his eight-year tenure and hand the baton to Chief Commercial...

There are many over-the-counter probiotic food additions that one can eat, and now the FDA has approved the first oral microbiome to be used as a therapeutic. The...

After declaring bankruptcy two months ago and closing all production sites, Akorn is yanking its products from the market. Akorn on Wednesday put out a voluntary ...

AstraZeneca and Merck & Co.’s Lynparza may have claimed a broad trial success—and European approval—in prostate cancer, but the FDA has its reservations. In b...

New equipment added to San Diego and Melbourne facilities will help with clinical scale and global capacity shortages PHILADELPHIA -April 18, 2023- PCI Pharm...